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Objective: Vaccination is the most effective way to prevent seasonal influenza and its severe outcomes. The objective of our 
study was to synthesize information on seasonal influenza vaccination policies, recommendations and practices in place in 
2011 for all countries and areas in the World Health Organization’s (WHO) Western Pacific Region.
Methods: Data were collected via a questionnaire on seasonal influenza vaccination policies, recommendations and 
practices in place in 2011.
Results: Thirty-six of the 37 countries and areas (97%) responded to the survey. Eighteen (50%) reported having 
established seasonal influenza vaccination policies, an additional seven (19%) reported having recommendations for risk 
groups for seasonal influenza vaccination only and 11 (30%) reported having no policies or recommendations in place. Of 
the 25 countries and areas with policies or recommendations, health-care workers and the elderly were most frequently 
recommended for vaccination; 24 (96%) countries and areas recommended vaccinating these groups, followed by pregnant 
women (19 [76%]), people with chronic illness (18 [72%]) and children (15 [60%]). Twenty-six (72%) countries and 
areas reported having seasonal influenza vaccines available through public funding, private market purchase or both. Most 
of these countries and areas purchased only enough vaccine to cover 25% or less of their populations.
Discussion: In light of the new WHO position paper on influenza vaccines published in 2012 and the increasing availability 
of country-specific data, countries and areas should consider reviewing or developing their seasonal influenza vaccination 
policies to reduce morbidity and mortality associated with annual epidemics and as part of ongoing efforts for pandemic 
preparedness.
Influenza is an acute viral infection transmitted person to person predominately through droplet spread. Worldwide, annual influenza epidemics result in 
about 3 to 5 million cases of severe illness and about 
250 000 to 500 000 deaths.1 All age groups can be 
seriously affected, with the greatest risk of complications 
occurring among children aged under two years, adults 
65 years or older, pregnant women and people of any 
age with certain chronic medical conditions or weakened 
immune systems.2 The most effective way to prevent 
seasonal influenza and its severe outcomes is through 
vaccination, and safe and effective vaccines have been 
used for more than 60 years.3 A recent systematic review 
of the scientific literature reported a pooled efficacy of 
83% (95% confidence interval: 69%–91%) for trivalent 
live attenuated influenza vaccine in children six months 
to seven years of age.4 The same review reported that 
trivalent inactivated influenza vaccines had an efficacy 
of 59% (95% confidence interval: 51%–67%) in healthy 
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adults 18–65 years of age and provided significant 
protection against medically attended influenza. There is 
also evidence demonstrating the socioeconomic benefits 
of vaccinating people against influenza.5–7
In the Western Pacific Region of the World Health 
Organization (WHO), awareness of the public health 
importance of influenza and the need for pandemic 
preparedness has increased in recent years motivated by 
the re-emergence of highly pathogenic avian influenza 
A(H5N1) in 2003–2004 and subsequently by the 
occurrence of the influenza A(H1N1) pandemic in 2009. 
The Region currently has three WHO collaborating 
centres for Reference and Research on Influenza and 
21 National Influenza Centres in 15 countries that 
monitor the impact and evolution of influenza viruses 
and provide isolates for global vaccine strain selection 
and formulation.8,9 Despite the Western Pacific Region 
contributing more than 76% of the total virus isolates 
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Western Pacific Region (Figure 1).12 Data collection 
was supported by regional members of GISRS,13 staff 
of the Expanded Programme on Immunization and WHO 
country or liaison offices. The questionnaire requested 
data and information on seasonal influenza vaccination 
policies, recommendations and practices in place in 
2011, including: existence of a national vaccination 
policy; funding mechanisms for vaccines (public funding, 
private market purchase or both); recommendations for 
risk groups to target for vaccination; types of influenza 
vaccines available; number of vaccine doses purchased 
and distributed in 2011; the time period (months) when 
influenza vaccines were available for the 2011 southern 
hemisphere and the 2011–2012 northern hemisphere 
seasons; and the peak month(s) of influenza activity. 
Incomplete surveys were followed up until all information 
was provided. For one area that did not respond to the 
survey, data were extracted from the WHO 2010 Survey 
for the Global Mapping of Seasonal Influenza Vaccine 
(unpublished data). The proportion of the total population 
potentially covered with influenza vaccine was calculated 
using country and area population data from the WHO 
web site.12 Ethics review was not required for this study 
as it was a survey of policy and national-level practices, 
not a study involving individual human participants.
submitted to the WHO Global Influenza Surveillance 
Response and System (GISRS) between 1998 and 2010 
for vaccine strain selection,10 influenza vaccination 
programmes have not been established consistently 
throughout the Region. These programmes facilitate 
governments’ health policies for influenza vaccination 
and provide the mechanisms for ensuring the target 
groups for vaccination actually receive vaccines.
To describe seasonal influenza vaccination policies, 
recommendations and use in the Western Pacific 
Region, WHO conducted a survey in 2012. This report 
summarizes the results from the survey in the context 
of the new WHO position paper on vaccines against 
influenza that recommended pregnant women be given 
the highest priority for vaccination; it also recommended 
seasonal influenza vaccination for, in no order of priority, 
health-care workers, children aged six to 59 months, the 
elderly and persons with chronic medical conditions.11
METHOD
Data were collected via a survey conducted by WHO 
from July to October 2012. The questionnaire was sent 
electronically to all 37 countries and areas of WHO’s 
Figure 1. Countries and areas in WHO Western Pacific Region*
*  American Samoa; Australia; Brunei Darussalam; Cambodia; China; the Commonwealth of the Northern Mariana Islands; 
Cook Islands; the Federated States of Micronesia; Fiji; French Polynesia; Guam; Hong Kong (China); Japan; Kiribati; 
the Lao People’s Democratic Republic; Macao (China); Malaysia; the Marshall Islands; Mongolia; Nauru; New Caledonia; 
New Zealand; Niue; Palau; Papua New Guinea; the Philippines; the Pitcairn Islands; the Republic of Korea; Samoa; Singapore; 
Solomon Islands; Tokelau; Tonga; Tuvalu; Vanuatu; Viet Nam; and Wallis and Futuna
 Countries and areas in 
WHO Western Pacifi c Region
WPSAR Vol 4, No 3, 2013 | doi: 10.5365/wpsar.2013.4.1.009www.wpro.who.int/wpsar 3
Influenza vaccine use in the Western PacificWestern Pacific Global Influenza Surveillance and Response System
RESULTS
Data were available from 36 (97%) of the 37 countries 
and areas of the Western Pacific Region; 35 countries 
and areas responded to the questionnaire and one had 
responded to the WHO 2010 Survey for the Global 
Mapping of Seasonal Influenza Vaccine. Data were 
not available from the Commonwealth of the Northern 
Mariana Islands.
Seasonal infl uenza vaccination policies
Eighteen (50%) countries and areas, comprising 
93% of the total population of the Western Pacific 
Region, reported having established seasonal influenza 
vaccination policies; an additional seven (19%) reported 
providing influenza vaccination recommendations only 
for risk groups (but not as part of a vaccination policy). 
Eleven countries and areas (30%) reported having no 
policy or recommendations in place. Of the 25 countries 
and areas with policy or recommendations, health-
care workers and the elderly were most frequently 
recommended for vaccination; 24 (96%) countries 
and areas recommended vaccinating these groups, 
followed by pregnant women (19 [76%]), people with 
chronic illness (18 [72%]) and children (15 [60%]). 
Other groups included in policies or recommendations 
were children only or the elderly with chronic illnesses, 
laboratory workers and first responders, caregivers of 
high-risk persons and Hajj pilgrims (Table 1).
Seasonal infl uenza vaccine use
Of the 36 participating countries and areas in the 
Region, 26 (72%) reported that seasonal influenza 
vaccine was available through public funding, private 
market purchase or both (Table 2). Cambodia, Cook 
Islands, Singapore and Viet Nam reported that seasonal 
influenza vaccine was available through private market 
purchase only. The remaining 22 countries and areas 
reported that influenza vaccine was purchased by the 
government (seven countries and areas) or was available 
through both government and private market purchase 
(15 countries and areas). Ten (28%) countries and 
areas reported that seasonal influenza vaccine was not 
available.
Of the 26 countries and areas with influenza vaccine 
available, seven (27%) reported using only inactivated, 
non-adjuvanted, southern hemisphere formulation 
vaccine for the 2011 season. Five countries and areas 
(19%) reported using both southern and northern 
hemisphere formulation vaccines, of which three used 
inactivated, non-adjuvanted vaccine and two used both 
non-adjuvanted and adjuvanted inactivated vaccines. 
The remaining 14 countries and areas (54%) reported 
using northern hemisphere formulation vaccines, 12 of 
which used inactivated, non-adjuvanted vaccines. Palau 
reported using both inactivated, adjuvanted vaccine 
and live attenuated vaccine. Wallis and Futuna reported 
using inactivated, adjuvanted vaccine (Table 2).
For the 21 countries and areas that reported the 
number of doses of vaccine purchased, the estimated 
proportion of the total population that could be covered 
by the purchased amount ranged from 0.3% in Cook 
Islands to 99.7% in Tokelau. Most countries and 
areas purchased enough to cover less than 25% of 
their total populations. For the 17 countries and areas 
that reported the amount of vaccine distributed, the 
estimated proportion of the total population that could 
be covered again ranged from 0.3% in Cook Islands to 
99.7% in Tokelau, with most estimates being less than 
20% (Table 2).
The majority of countries obtained their vaccine 
supply from international manufacturers. Australia, 
China and the Republic of Korea reported both domestic 
production and importation of influenza vaccines. Japan 
reported using only domestically produced vaccines 
(Table 2).
Peak infl uenza seasons and vaccination timing
Reported periods of peak influenza activity tended to 
coincide with the winter and spring months in temperate 
countries and areas and throughout the year in tropical 
countries and areas. For those countries and areas using 
southern hemisphere formulation vaccine, peak months 
of activity occurred from June to November, except for 
Macau (China) that reported having peak activity during 
February and March. Most countries and areas using 
the northern hemisphere formulation vaccine reported 
peak influenza months from December to April, although 
peaks before this period were reported by seven countries 
and areas, five in the Pacific. Those countries and areas 
that reported using both the southern and northern 
hemisphere formulation vaccines tended to report 
influenza activity throughout the year. Most countries 
and areas conducted their vaccination programmes in 
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Table 1. Recommendations for vaccine recipients by country and area, WHO Western Pacific Region, 2011
Country/area Policy
Recommended recipients
Other risk groups and comments
HCW Elderly (years)
Chronic 
illness
Pregnant 
women
Children 
(age)
American Samoa* N Y Y (> 40) Y Y Y (6m–18y)
Australia Y Y Y (> 65) N Y N Aboriginal and Torres Strait Islanders > 15 years; children 
> 6 months with pre-disposing conditions, residents of nursing 
homes and other long-term care facilities, homeless people and 
their caregivers, people who may transmit to those with high risk of 
infl uenza complications, people in the poultry industry during avian 
infl uenza activity, people providing essential services, workers in 
other industries, travellers
Brunei Darussalam Y Y Y (> 60) N Y Y (6–23) Hajj pilgrims
Cambodia N Currently no recommendations exist
China Y Y Y (> 60) N Y Y (6–60) Close contacts of persons at high risk (staff of kindergartens and 
nursery schools, household contacts and caregivers)
Cook Islands* N Y Y (> 60) N Y N
Federated States of Micronesia* N Y Y (< 50) Y Y Y (6m–18y) All adults over the age of 18
Fiji N Y Y Y Y N
French Polynesia (France) Y Y Y (> 60) Y Y N Persons with obesity (body mass index > 30)
Guam Y Y Y (≥ 50) Y Y Y (6m–18y) Adults aged 19–49 years with high-risk medical conditions (e.g. 
asthma, heart conditions, lung conditions)
Note: Follow CDC recommendation for universal infl uenza vaccine 
for any persons.
Hong Kong (China) Y Y Y
(≥ 50)
Y Y Y (6 to 71) Residents of nursing homes and long-term residents of homes for 
the disabled; poultry workers, pig farmers and pig-slaughtering 
industry personnel
Japan Y N Y (> 65) N N N
Kiribati N – – – – –
Lao People’s Democratic Republic N Y Y (> 50) Y Y Y
Macau (China) Y Y Y (> 60) Y Y Y (6m-18y)
Malaysia Y Y N Y N N Hajj pilgrims, elderly with one or more chronic illness
Marshall Islands* N Y Y - Y Y
Mongolia Y Y Y (> 60) N N N
Nauru N – – – – –
New Caledonia Y Y Y (> 65) Y N N Air and cruise crews
New Zealand Y Y Y (> 65) Y Y N Persons of all ages with chronic conditions including children 
> 6 months with defi ned pre-disposing conditions
Niue Y Y Y (> 65) Y N N Children < 6 years with chronic illness
Commonwealth of the Northern 
Mariana Islands
N – – – – –
Palau† Y Y Y (> 50) Y Y Y (≥ 6) All fi rst responders
Papua New Guinea N – – – – –
Philippines Y Y Y (> 60) Y Y Y (6m–18y) Healthy persons providing essential and emergency community 
services, students and others in institutional settings
Public health policy is in place only for the targeting of 
indigent elderly citizens. All other groups are public health 
recommendations.
Pitcairn Islands N Currently no recommendations exist
Republic of Korea Y Y Y (> 50) Y Y Y (6–60) Residents of nursing homes and other long-term care facilities, 
caregivers of children < 6 months, infection control personnel and 
workers in poultry-related industries
Samoa N Currently no recommendations exist
Singapore Y Y Y (> 65) Y Y Y (6–60) Children 6 months to 18 years on long-term aspirin therapy, 
caregivers of children < 6 months, persons at high risk of 
complications of infl uenza
Solomon Islands N – – – – –
Tokelau N – – – – –
Tonga N – – – – –
Tuvalu N – – – – –
Vanuatu N – – – – –
Viet Nam N Y Y (> 65) Y N Y (6–96)
Wallis and Futuna Y Y Y (> 65) Y Y Y (6–60)
CDC – Centers for Disease Control and Prevention; HCW – health care workers; m – months; N – no; y – years; Y – Yes.
* These countries and areas reported not having established policy but having recommendations for seasonal influenza vaccination.
† Data from the WHO 2010 Global Influenza Vaccine Survey.
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the months before or during periods of peak influenza 
activity (Table 3).
DISCUSSION
Of the 36 countries and areas included in this study, 
18 (50%) reported having an established policy 
regarding seasonal influenza vaccination, which is a 
larger proportion than 40% of the 157 countries that 
reported having a policy in a global survey.14 Seven 
(19%) additional countries and areas in the Western 
Pacific Region reported providing recommendations 
for risk groups for seasonal influenza vaccination, but 
these were not part of an established policy. However, 
unlike the rapid increase from 2004 in the number of 
countries in the Americas using seasonal influenza 
vaccine,15 only three (8%) countries and areas in the 
Western Pacific Region reported introducing influenza 
vaccine after 2004. In 2011, influenza vaccine was not 
available in 10 (28%) countries and areas, and influenza 
vaccine policy or recommendations were not available in 
11 (30%) countries and areas. Therefore, the increase 
in influenza surveillance and response capacity and 
pandemic preparedness in the Western Pacific Region in 
Table 2. Vaccination information from countries and areas reporting having seasonal influenza vaccines available 
in 2011, WHO Western Pacific Region
Country
Year 
vaccine 
introduced
Formu-
lation
Type of 
vaccine
Public sector or 
private market 
purchase
No. doses 
purchased 
(% of population)
No. doses 
distributed 
(% of population)
Source 
(domestic or 
international)
American Samoa 2003 NH TIV Both 8900 (12.1) 6502 (11.5) International
Australia 1997 SH TIV Both 3 776 512 (16.9) – – Both
Brunei 
Darussalam
2003 Both TIV Both 28 000 (6.9) 26 800 (6.6) International
Cambodia – Both TIV Private – – – – International
China 1998 NH TIV Both – – – – Both
Cook Islands 2010 Both TIV Private 60 (0.3) 60 (0.3) International
Federated States 
of Micronesia
2000 NH TIV Public 17 000 (16.6) 10 000 (9.3) International
French Polynesia 2002 NH TIV Both 16 000 (6.0) – – International
Guam 1997 NH TIV Public 7300 (4.0) – – International
Hong Kong 
(China)
1998 NH TIV Both 480 000 (6.8)‡ 408 000 (5.8)‡ International
Japan 1951 NH TIV Both 50 000 000 (39.2) 50 000 000 (39.2) Domestic
Macau (China) 2000 SH TIV Both 110 000 (19.9) 85 000 (15.4) International
Malaysia 1988 Both TIV & ATIV Both† – – – – International
Marshall Islands 2002 NH TIV Public 10 000 (18.4) 10 000 (18.4) International
Mongolia 1979 NH TIV Both 17 000 (0.6) 17 000 (0.6) International
New Caledonia 1994 NH TIV Both 18 460 (7.5) 18 460 (7.5) International
New Zealand 1997 SH TIV Both 988 000 (22.6) 988 000 (22.6) International
Niue 2000 SH TIV Public 200 (13.4) 200 (13.4) International
Palau* 1996 NH TIV & LAIV Public 5000 (24.3) – – –
Philippines – SH TIV Both – – – – International
Pitcairn Islands 1997 SH TIV Both 30 (57.7) 22 (42.3) International
Republic of Korea 1997 NH TIV Both 3 986 900 (8.2)§ 3 986 900 (8.2)§ Both
Singapore 1988 Both TIV & ATIV Private – – – – International
Tokelau 2009 SH TIV Public 1466 (99.7) 1466 (99.7) International
Viet Nam 2008 NH TIV Private – – – – International
Wallis and Futuna 2004 NH ATIV Public 1600 (12.1) 1530 (11.5) International
ATIV – adjuvanted trivalent inactivated influenza vaccine; LAIV – live attenuated influenza vaccine; NH – northern hemisphere formulation; SH – southern 
hemisphere formulation; and TIV – trivalent inactivated influenza vaccine.
* Data fro m the WHO 2010 Global Influenza Vaccine Survey.
† Public funding limited to frontline health-care workers.
‡ Estimation based on vaccine purchased by the government and claims made by private doctors to the Government’s Vaccine Subsidy Schemes.
§ Public sector purchase figure, i.e. does not include the 9–10 million doses available through private market purchase.
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result, the number of countries that produce seasonal 
influenza vaccine has increased both globally and in 
the Western Pacific Region.14,21,22 In 2008, WHO 
awarded grants to manufacturers in three countries in 
the Region, namely China, the Republic of Korea and 
Viet Nam. The manufacturer in the Republic of Korea 
has since licensed both pandemic and trivalent seasonal 
vaccines; the other two manufacturers are at different 
stages of development.22 Despite the increase in vaccine 
production, this study shows the lack of concomitant 
vaccine use as most countries and areas that reported 
influenza vaccine use reported purchasing and/or using 
only enough vaccine to cover less than 25% of their total 
populations. Global seasonal influenza manufacturers 
reported that, despite growth in production capacity 
at the global, regional and national levels, more than 
two-thirds of countries distributed vaccine to cover only 
10% of their populations.14 Unfortunately, as risk-group 
population data were not collected by this study, it was 
not determined whether the reported number of doses of 
vaccine purchased by countries and areas were sufficient 
to cover the high-risk groups identified in vaccination 
policies or recommendations.
The second WHO Global Action Plan for influenza 
vaccines will place more focus on increasing seasonal 
vaccine use.20 Reimbursement; communication; and, to 
a lesser extent, a country’s development status have been 
previously correlated with vaccine use.14 In China, the 
experiences in Beijing and Shaanxi suggest that effective 
promotional campaigns with reimbursement policies 
increase uptake in both high- and low-income areas.23 
Similarly, in a survey of 10 countries, higher rates of 
vaccination were generally observed in countries with 
existing recommendations or vaccination programmes.19
One component of a successful vaccination 
programme is a surveillance system that monitors the 
impact of vaccination on disease burden. The results from 
this study show that most countries and areas schedule 
their vaccination campaign before or during their peak 
influenza season, but they also show that several countries 
and areas reported peak seasons inconsistent with their 
current vaccination schedule. Given the progress made 
in influenza surveillance capacity development in the 
Western Pacific Region in recent years, countries and 
areas are better able to understand the epidemiology of 
influenza in their populations, including seasonal patterns, 
and can now better match vaccination programmes with 
influenza seasonality.24 In addition, to support policy 
recent years16 has not been consistentacross the Region 
in the use of vaccines as an effective control measure. 
This is particularly true in Pacific island nations.
The 2012 WHO position paper on vaccines against 
influenza recommended that pregnant women be given 
the highest priority for vaccination in countries initiating or 
expanding seasonal influenza vaccination programmes. 
This recommendation was based on the risk of severe 
disease in this group, the evidence of the safety of trivalent 
inactivated influenza vaccines throughout pregnancy and 
the effectiveness of vaccines in preventing illness for the 
women and their infants.11 The vaccination of pregnant 
women has also been shown to be cost-effective in the 
United Kingdom and Northern Ireland.17 Although the 
proportion of countries and areas in the Western Pacific 
Region that have recommended pregnant women as 
a risk group for vaccination (76%) is higher than the 
proportion reported from Europe (37%),18 more work is 
needed to promote the inclusion of this risk group in 
existing and new policies and recommendations in the 
Region.
The new WHO position paper also recommended 
seasonal influenza vaccination for, in no order of priority, 
health-care workers, children aged six to 59 months, 
the elderly and persons with chronic medical conditions. 
All 18 countries and areas in the Region with public 
policies for seasonal influenza vaccination recommended 
vaccination for health-care workers and the elderly, which 
is consistent with reports from European countries18 and 
the global vaccination survey.14 Children were included 
in 15 (60%) country and area vaccination policies or 
recommendations in the Region, a much larger proportion 
than that reported by six (22%) of 27 European 
countries.18 A global study comparing 10 countries in 
2006 showed that the highest vaccination coverage 
rates for children were from the three Asian countries 
in the study, suggesting that paediatric vaccination is 
important in the Asian region.19 Persons at high risk of 
complications from influenza and/or those with chronic 
medical conditions were recommended for influenza 
vaccination in the policies of 18 (72%) countries and 
areas in the Region, higher than the proportions reported 
from European countries.18
Since 2006, there has been a global push to 
increase both the production and use of seasonal 
influenza vaccines through activities contained in the 
WHO Global Action Plan on influenza vaccines.20 As a 
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and vaccination recommendations, GISRS members 
in the Region have developed a workplan to improve 
surveillance systems and to promote the implementation 
of special studies for additional data required.25
This study shows that more than two-thirds of the 
countries and areas in WHO’s Western Pacific Region 
have either seasonal influenza vaccination policies or 
recommendations for vaccinating high risk groups. 
Table 3. Reported peak influenza month(s) and months of influenza vaccine availability, WHO Western Pacific 
Region, 2011
Country Formu-lation
2011 2012
Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May
American Samoa* NH v
Australia SH v v v v v v v v
Brunei Darussalam Both v v v v v v v v v v v v v v v v
Cambodia Both v v v v v v v v v v v v v v v v
China NH v v v v v v v v
Cook Islands Both v v
Federated States of 
Micronesia
NH v v v v v v v v v
Fiji –
French Polynesia NH v v v v
Guam NH v v v v v v v v v v v v v v
Hong Kong (China) NH v v v v v v v v v v v v v v v v
Japan NH v v v v v v v
Karibati –
Lao People’s 
Democratic Republic
–
Macau (China) SH v v v v v v v v
Malaysia Both v v v v v v v v v v v v v v v v
the Marshall Islands NH v
Mongolia NH v v v v
Nauru –
New Caledonia NH v v v v v v
New Zealand SH v v v v v
Niue SH v v v v v v v v v v
Palau† NH
Papua New Guinea –
Philippines SH v
Pitcairn Islands SH v
Republic of Korea‡ NH v v v v v v v v
Samoa –
Singapore Both v v v v v v v v v v v v v v v v
Solomon Islands –
Tokelau* SH
Tonga –
Tuvalu –
Vanuatu –
Viet Nam NH
Wallis/Futuna NH v
Key: Shaded months are the reported peak months for influenza illness; v – vaccine available.
NH – northern hemisphere formulation; SH – southern hemisphere formulation;  “–” – influenza vaccine currently not available.
* American Samoa and Tokelau reported unknown vaccination month(s).
† Data from the WHO 2010 Global Influenza Vaccine Survey – seasonality and vaccine availability not reported.
‡ Public sector-purchased vaccine available October–December
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In light of the new WHO position paper on vaccines 
against influenza published in 2012 and the increasing 
availability of country-specific data, countries and areas 
should consider reviewing or developing their seasonal 
influenza vaccination policies or recommendations to 
reduce morbidity and mortality associated with annual 
epidemics and as part of ongoing efforts for pandemic 
preparedness.
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